eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
5/2009
vol. 4
 
Share:
Share:
more
 
 
abstract:
Case report

Long-term infliximab treatment in a patient with fistualizing Crohn’s disease

Maria Wiśniewska-Jarosińska
,
Paweł Wichan
,
Jan Chojnacki

Przegląd Gastroenterologiczny 2009; 4 (5): 277–281
Online publish date: 2009/11/09
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction in the last decade the biological treatment directed against anti-TNF-α for Crohn’s disease improved the effectiveness of the therapy and at the same time increased the percentage of clinical remissions achieved. Anti-TNF-α therapies favourable affect clinical symptoms and reduce the inflammatory indices of the disease. However, the long-term biological treatment carries the risk of the loss of response and adverse events, which sometimes can be very serious. Among these agents, infliximab – a chimeric, mouse and human, monoclonal antibody, has been used in the treatment of active Crohn’s disease for the longest time. Presenting a case report of a young woman with fistualizing Crohn’s disease the authors want to share their experience and point out the therapeutic problems, which can arise during the long-term biological treatment with anti-TNF-α agents.
keywords:

Crohn’s disease, biological therapy with monoclonal antibodies anti-TNF-α, infliximab

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe